Cancer prevention: targeted agents to stop cancer early in high-risk people
Official title: Cancer Prevention-Interception Targeted Agent Discovery Program at Fox Chase Cancer Center
Funded at Research Inst of Fox Chase Can Ctr · NIH-11415061 · Data updated 2026-11-12
A team at Fox Chase Cancer Center is building a pipeline to develop and test targeted drugs that could prevent cancer or catch it early in people with strong hereditary cancer risk.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,513,641 |
| NIH project number | 5U54CA272686-05 |
| Project ID | NIH-11415061 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with hereditary cancer risk or germline mutations who are enrolled in risk assessment programs and families with high cancer risk.
✕Less likely to help
Individuals without hereditary cancer risk or germline mutations may not directly benefit from these targeted prevention strategies.
What this research studies
This program brings together experts in cancer prevention, genetics, and drug discovery to create a pipeline for preventing cancer in people with inherited risk. It focuses on validating targets, identifying and screening potential agents, and testing them in early-stage models to see if they can stop progression before cancer develops. The center leverages a large registry of high-risk families and germline mutation carriers to guide and prioritize interventions. The work aligns with real-world prevention, aiming to translate molecular findings into actionable preventive options for at-risk individuals.
Why it matters
Potential benefit: If successful, the program could lead to preventive therapies that reduce cancer risk in genetically high-risk people.
How similar studies have gone: Previous prevention approaches have shown that targeted agents can modulate early lesions; this project aims to extend that success to high-risk populations.
Where this research is happening
-
Research Inst of Fox Chase Can Ctr
Philadelphia, United States Active
Researchers
- Principal investigator: Clapper, Margie L. — Research Inst of Fox Chase Can Ctr
- Study coordinator: Clapper, Margie L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.